Leucid Bio

Thinking laterally about CAR-T. Develops Autologous and Allogeneic cell and gene Therapies for hard to treat cancers.

General Information
Company Name
Leucid Bio
Founded Year
2014
Location (Offices)
London, United Kingdom +1
Founders / Decision Makers
Number of Employees
23
Industries
Biotechnology, Health Care
Funding Stage
Series A
Social Media

Leucid Bio - Company Profile

Leucid Bio is a UK-based biotechnology startup founded in 2014, with a focus on developing Autologous and Allogeneic cell and gene Therapies for hard-to-treat cancers. The company's slogan, "Thinking laterally about CAR-T," reflects its innovative approach to progressing novel CAR T therapies that aim to produce a better and more durable response than previous generations. This innovation promises to improve treatment outcomes and save the lives of patients with refractory cancers. In its latest funding round, Leucid Bio raised a significant £11.50M in a Series A investment on 21 October 2021. The investors in this round included prominent names such as Sofinnova Partners, Vulpes Investment Management, Epidarex Capital, British Business Bank, and 2invest. These investments serve as a testament to the confidence that industry leaders have in the potential of Leucid Bio's innovative approach to CAR T therapies. Overall, Leucid Bio's dedication to pushing the boundaries of CAR T therapy and its ability to attract substantial investments from reputable sources such as Sofinnova Partners and Epidarex Capital position it as a noteworthy player in the biotechnology and healthcare industries. This demonstrates the company's potential to make a lasting impact on the treatment of challenging cancers, making it an intriguing prospect for venture capital investors seeking opportunities in the life sciences sector.

Taxonomy: CAR-T therapies, Autologous cell therapies, Allogeneic cell therapies, Gene therapies, Hard-to-treat cancers, Novel CAR T therapies, Treatment outcomes, Refractory cancers, Cancer treatment, Medical innovation, Precision medicine, Immunotherapy, Life-saving therapies

Funding Rounds & Investors of Leucid Bio (1)

View All
Funding Stage Amount No. Investors Investors Date
Series A £11.50M 5 2invest, Vulpes Investment Management Pte Ltd 21 Oct 2021

Latest News of Leucid Bio

View All

No recent news or press coverage available for Leucid Bio.

Similar Companies to Leucid Bio

View All
Curocell - Similar company to Leucid Bio
Curocell Fight against hopelessness
aratinga.bio - Similar company to Leucid Bio
aratinga.bio aratinga.bio develops immunotherapies to treat cancer, including CAR T-cell platform for hematological and solid tumors.
SpecificiT Pharma - Similar company to Leucid Bio
SpecificiT Pharma Pioneering personalized cancer therapies with a novel approach using Minor Histocompatibility Antigens to target hematological cancers.
Prescient Therapeutics - Similar company to Leucid Bio
Prescient Therapeutics A clinical stage oncology company developing personalised medicine approaches to cancer; cellular & targeted therapies.
ImmuneCyte, Inc. - Similar company to Leucid Bio
ImmuneCyte, Inc. A HealthBanks Biotech Company